The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC).
J. A. de Souza
No relevant relationships to disclose
B. N. Polite
No relevant relationships to disclose
S. Zhu
No relevant relationships to disclose
J. J. Dignam
No relevant relationships to disclose
N. J. Meropol
Consultant or Advisory Role - Genentech
M. J. Ratain
Consultant or Advisory Role - Genentech; Mylan; Teva
Research Funding - Bristol-Myers Squibb
L. N. Newcomer
Employment or Leadership Position - UnitedHealth Group
Stock Ownership - UnitedHealth Group
G. C. Alexander
No relevant relationships to disclose